Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.
Also called NCT03566693
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 176 participants
- Registry
-
NCT03566693
-
- Other papers using this trial's data
- Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial
- Rapid improvements in glycemic management with use of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin: 3-month analysis of the MOBILE study
- With or Without Residual C-Peptide, Patients with Type 2 Diabetes Realize Glycemic Benefits from Real-Time Continuous Glucose Monitoring
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03566693. Randomized; no masking; primary purpose treatment. Start 2018-07-30 (actual); primary completion 2021-01-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
- Acronym
- MOBILE
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Device)
- Dexcom G6 CGM System
- Intervention (Device)
- Blood glucose meter
- Lead sponsor
- DexCom, Inc.
- Collaborator
- Jaeb Center for Health Research
Record details
- Record id
cardio:ct-nct03566693- Content hash
0c261b06792d1acc83cf773cde5c69157076158bff307b88042d9d978cc26ad8